Pharmena (WAR:PHR) Cyclically Adjusted Revenue per Share: zł1.50 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:PHR Pharmena SA WAR:PHR
54 GF Score
Price zł3.08
GF Value zł5.66
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Pharmena Cyclically Adjusted Revenue per Share?

Pharmena WAR:PHR -0.32% 54 Cyclically Adjusted Revenue per Share is zł1.50 as of Mar. 2026. GuruFocus rates WAR:PHR with a GF Score™ of 54/100 and a GF Value™ of zł5.66 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Pharmena's adjusted revenue per share for the three months ended in Mar. 2026 was zł0.038. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł1.50 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Pharmena's average Cyclically Adjusted Revenue Growth Rate was -12.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Pharmena was 1.60% per year. The lowest was -9.00% per year. And the median was -3.70% per year.

As of today (2026-07-30), Pharmena's current stock price is zł3.08. Pharmena's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł1.50. Pharmena's Cyclically Adjusted PS Ratio of today is 2.05.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharmena was 7.76. The lowest was 1.61. And the median was 3.18.


Pharmena  (WAR:PHR) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Pharmena's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.08/1.50
=2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Pharmena was 7.76. The lowest was 1.61. And the median was 3.18.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Pharmena Cyclically Adjusted Revenue per Share Related Terms


Pharmena Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Pharmena's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmena Cyclically Adjusted Revenue per Share Chart

Pharmena Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.68 1.99 1.91 1.76 1.50

Pharmena Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.72 1.66 1.58 1.50 1.50

WAR:PHR vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Pharmena's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmena Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmena's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharmena's Cyclically Adjusted PS Ratio falls into.


WAR:PHR
54GF Score
Pharmena SA WAR:PHR
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmena Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharmena's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.038/163.0700*163.0700
=0.038

Current CPI (Mar. 2026) = 163.0700.

Pharmena Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.450 99.552 0.737
201609 0.486 99.064 0.800
201612 0.523 100.366 0.850
201703 0.292 101.018 0.471
201706 0.382 101.180 0.616
201709 0.313 101.343 0.504
201712 0.369 102.564 0.587
201803 0.420 102.564 0.668
201806 0.310 103.378 0.489
201809 0.385 103.378 0.607
201812 0.367 103.785 0.577
201903 0.365 104.274 0.571
201906 0.228 105.983 0.351
201909 0.307 105.983 0.472
201912 0.218 107.123 0.332
202003 0.231 109.076 0.345
202006 0.167 109.402 0.249
202009 0.274 109.320 0.409
202012 0.231 109.565 0.344
202103 0.296 112.658 0.428
202106 0.313 113.960 0.448
202109 0.359 115.588 0.506
202112 0.398 119.088 0.545
202203 0.326 125.031 0.425
202206 -0.311 131.705 -0.385
202209 0.000 135.531 0.000
202212 1.694 139.113 1.986
202303 0.014 145.950 0.016
202306 0.001 147.009 0.001
202309 0.000 146.113 0.000
202312 0.097 147.741 0.107
202403 0.001 149.044 0.001
202406 0.013 150.997 0.014
202409 0.002 153.439 0.002
202412 0.008 154.660 0.008
202503 0.035 157.021 0.036
202506 0.035 157.509 0.036
202509 0.037 158.000 0.038
202512 0.035 158.320 0.036
202603 0.038 163.070 0.038

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł1.50 mean?
Pharmena (WAR:PHR) has a Cyclically Adjusted Revenue per Share of zł1.50 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharmena and its competitors.
Is Pharmena's Cyclically Adjusted Revenue per Share too high?
Pharmena's current Cyclically Adjusted Revenue per Share is zł1.50. Overall, Pharmena has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pharmena's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Pharmena's Cyclically Adjusted Revenue per Share of zł1.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Pharmena and its competitors. Pharmena's current Cyclically Adjusted Revenue per Share is zł1.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmena stock overvalued right now?
Based on GuruFocus' analysis, Pharmena (WAR:PHR) is currently considered Possible Value Trap. The stock's GF Value™ is zł5.66, compared to a current price of zł3.08 — trading 45.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł1.50. Pharmena's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Pharmena (WAR:PHR), the current Cyclically Adjusted Revenue per Share is zł1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmena (WAR:PHR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmena stock appears to be undervalued. The current stock price of zł3.08 is trading 45.6% below its estimated GF Value™ of zł5.66. GuruFocus considers Pharmena to be Possible Value Trap.

Key valuation signals for WAR:PHR:

  • Cyclically Adjusted Revenue per Share: zł1.50
  • GF Value™: zł5.66 vs. price of zł3.08 (45.6% below fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the WAR:PHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmena Business Description

Address Ulica Wolczanska 178, Lodz, POL, 90-530
Pharmena SA produces cosmeceuticals and pharmaceuticals. The company's activity focuses on three areas such as research in the USA and Canada on the application of selected pyridinium salts in medicine in order to develop an anti-atherosclerosis drug on a global scale, Production and sales of innovative patented dermocosmetics and introduction into the market of an innovative dietary supplement for atherosclerosis prophylaxis. Its products include Menavitin, Dermena, Allerco and Thermi.
54GF Score

Get the complete analysis for WAR:PHR

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.08
Price
zł5.66
GF Value